Early work on “fully closed loop” automated insulin delivery systems was a focus at the American Diabetes Association’s Scientific Sessions last weekend.
Insulet and MiniMed shared updates on their efforts to develop the technology, which would allow people with diabetes to receive the insulin they need without meal announcements or pre-meal bolus insulin doses.
Insulet’s system is intended for people with Type 2 diabetes and removes the need for bolusing or programming the system altogether, while MiniMed’s device is for Type 1 and Type 2 diabetes and still has a bolus option.
Insulet also presented pivotal results of its next insulin patch pump, the Omnipod 6, which it plans to submit to the Food and Drug Administration this year.
Continuous glucose monitors were another hot topic at the conference, with discussions about sensors that can measure multiple analytes, not just glucose. Scientists talked about approaches to continuous ketone monitoring, after Abbott received Europe’s CE mark for the first glucose-ketone sensor.
Dexcom also shared the readout of a large study that it hopes will lead to broader coverage of its glucose sensors for people with diabetes who don’t take insulin.
Catch up on MedTech Dive’s coverage of the conference:
